CSI Market
Sign In | Register

Taysha Gene Therapies Inc (TSHA) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access TSHA quarterly Cash Flow →
Examining cash flow movements between Taysha Gene Therapies Inc and Dec 31 2021 reveals how Dec 31 2025 allocates cash as operating conditions evolve.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-109.00
Depreciation & amortization1.15
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Long-Lived Assets Held-for-use0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation13.30
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants1.20
Change In Fair Value Of Preferred Stock Tranche Liability-
Operating Lease Right Of Use Asset Amortization Expense1.36
Research And Development License Expense3.00
Increase Decrease In Accrued Expense And Other Liabilities6.29
Increase Decrease In Contract With Customer Liability-9.77
Property And Equipment In Accounts Payable And Accrued Expenses0.04
Right Of Use Asset Obtained In Exchange For Finance Lease Liability-
Capital Expenditures Incurred But Not Yet Paid-
Issuance Of Warrants In Connection With Private Placement-
Issuance Costs For Pre Funded Warrant Liability-
Non Cash Gain Loss On Extinguishment Of Debt-
Non Cash Change In Fair Value Of Term Loan0.83
Debt Issuance Costs Expensed Under Fair Value Option0.15
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-0.15
Increase (Decrease) in Accrued Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-1.73
Other Working Capital0.00
Other Noncash Income (Expense)0.30
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.04
Discontinued operations0.00
Net Cash flow from Operating Activities-93.09
Investing Activities
Capital Expenditures-0.74
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.13
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.60
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock1.38
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.23
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-84.30
Proceeds From Term Loan Net-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations141.64
Payment Of Shelf Registration Costs-
Proceeds From Trinity Term Loan Net-
Repayment Of Svb Term Loan-
Proceeds From Issuance Of Common Stock And Prefunded Warrants From Private Placement Net Of Placement Agent Commissions And Other Offering Costs-
Proceeds From Issuance Of Common Stock And Pre Funded Warrants From Underwritten Public Offering Net Of Underwriting Discounts And Sales Commissions And Other Offering Costs215.65
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities274.59
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-93.83
Total Cash Flow180.90
4 historic quarters locked

Sign in to unlock the full Taysha Gene Therapies Inc cash flow history.

Sign In Create Free Account

About Taysha Gene Therapies Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-115202

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License